Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Anti Mullerian Hormone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Anti Mullerian Hormone. Displaying page 1 of 1.
    EudraCT Number: 2004-003980-62 Sponsor Protocol Number: GBG 37 Start Date*: 2005-01-13
    Sponsor Name:GBG Forschungs GmbH
    Full Title: Prospective randomized multicenter study to prevent chemotherapy induced ovarian failure with the GnRH-Agonist Goserelin in young hormone insensitive breast cancer patients receiving anthracycline ...
    Medical condition: -young hormone insensitive breast cancer patients receiving anthracycline containing (neo-)adjuvant chemotherapy
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005337-37 Sponsor Protocol Number: ONC-2012-002 Start Date*: 2013-05-07
    Sponsor Name:Istituto Clinico Humanitas
    Full Title: ANTI-MULLERIAN HORMONE (AMH) AS A MARKER OF OVARIAN RESERVE IN YOUNG BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY + GnRH ANALOGUE
    Medical condition: Female subjects, aged <40yrs receiving adjuvant chemotherapy and ovarian suppression by means of GnRHa with the aim to assess the role of AMH as surrogate marker of the preservation of ovarian rese...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10006203 Breast cancer stage unspecified LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002979-17 Sponsor Protocol Number: MANCOR Start Date*: 2014-01-27
    Sponsor Name:IVI Sevilla
    Full Title: Comparative study between the usage of corifollitropin alfa and daily recombinant FSH in the ovarian stimulation of low responders
    Medical condition: Low response to ovarian stimulation
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002425-21 Sponsor Protocol Number: 11054 Start Date*: 2012-02-10
    Sponsor Name:University of Nottingham
    Full Title: Efficacy of Dehydroepiandrosterone to overcome the effect of ovarian aging
    Medical condition: Women having low ovarian reserve undergoing IVF/ICSI treatment
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003006-27 Sponsor Protocol Number: GEXGP24201 Start Date*: 2012-11-27
    Sponsor Name:Glycotope GmbH
    Full Title: A Phase II, Multicentre, Multinational, Randomised, Assessor-Blind Trial to Investigate the Efficacy and Safety of Various Dosages of FSH-GEX™ in Comparison With 150 IU Gonal-f® in Women Undergoing...
    Medical condition: women undergoing intracytoplasmatic sperm injection (ICSI) as part of assisted reproduction
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004872 10016398 Female infertility LLT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004298-15 Sponsor Protocol Number: 1601-ALC-002-MM Start Date*: 2018-10-04
    Sponsor Name:IVI Alicante
    Full Title: A Phase III multicentre, randomized, unblinded clinical trial to test the effect of treatment with recombinant LH prior to controlled ovarian stimulation in poor ovarian responder women with an a...
    Medical condition: ovarian stimulation in poor ovarian responders
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10071130 Controlled ovarian stimulation LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2021-002467-22 Sponsor Protocol Number: FSD-PSE-2021-09 Start Date*: 2021-07-02
    Sponsor Name:Fundacion Santiago Dexeus Font
    Full Title: Dual Trigger vs. GnRH-a Trigger for Elective Fertility Preservation. A randomized controlled trial.
    Medical condition: This study is a randomized controlled, superiority trial comparing the number of MII oocytes following final follicle maturation with dual trigger (250 μg rhCG + 0.2mg Triptorelin) or GnRH-a trigge...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004677-12 Sponsor Protocol Number: RHYTHM Start Date*: 2021-02-09
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI MODENA E REGGIO EMILIA - DIPARTIMENTO DI SCIENZE BIOMEDICHE, METABOLICHE E NEUROSCIENZE
    Full Title: Pharmacodynamics and safety of human recombinant luteinising hormone in hypogonadotropic hypogonadal men.
    Medical condition: Aquired hypogonadotropic hypogonadism
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10021012 Hypogonadotrophic hypogonadism LLT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003817-16 Sponsor Protocol Number: EMR200061-005 Start Date*: 2014-02-05
    Sponsor Name:Merck KGaA
    Full Title: A phase III, randomized, controlled, single-blind, multicentre, parallel arm trial to assess the efficacy and safety of Pergoveris® (follitropin alfa and lutropin alfa) and GONAL-f® (follitropin...
    Medical condition: Poor Ovarian Response i.e. a failure to respond adequately to standard ART (assisted reproductive technologies) protocols and to recruit adequate follicles
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004872 10033140 Ovarian disorder NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed) SE (Completed) EE (Completed) HU (Completed) BE (Completed) GB (Completed) NL (Completed) DK (Completed) LV (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-003862-15 Sponsor Protocol Number: 2013-601 Start Date*: 2013-11-19
    Sponsor Name:Jens Faber
    Full Title: Liraglutide in Polycystic Ovary Syndrome A randomised, double-blind, placebo-controlled study of the effect of Liraglutide in Polycystic ovary syndrome on risk markers of vascular Thrombosis
    Medical condition: Polycystic Ovary Syndrome (PCOS), especialy signs of early cardiovascular disease in women with PCOS.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-002662-12 Sponsor Protocol Number: GINECO-EN203b Start Date*: 2020-01-16
    Sponsor Name:ARCAGY-GINECO
    Full Title: A multicentric randomized phase II/III evaluating TSR-042 (anti-PD-1 mAb) in combination with Niraparib (parpi) versus Niraparib alone compared to chemotherapy in the treatment of metastatic or rec...
    Medical condition: metastatic or recurrent endometrial or ovarian carcinosarcoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014734 Endometrial cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014736 Endometrial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002654-95 Sponsor Protocol Number: NET-MS Start Date*: 2023-04-17
    Sponsor Name:FONDAZIONE ITALIANA SCLEROSI MULTIPLA ONLUS
    Full Title: No Evidence Of Disease Activity After Autologous Haematopoietic Stem Cell Transplantation In Aggressive Multiple Sclerosis
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000345-39 Sponsor Protocol Number: B9991032 Start Date*: 2019-02-19
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 2 Study to Evaluate Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib In Patients with BRCA or ATM Mutant Tumors
    Medical condition: locally advanced (primary or recurrent) or metastatic solid tumors with a pathogenic or likely pathogenic germline or loss-of-function somatic BRCA1, or BRCA2, or ATM gene defect
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10065147 Malignant solid tumor LLT
    20.0 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) BE (Completed) DK (Completed) ES (Ongoing) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-003788-67 Sponsor Protocol Number: FS1306 Start Date*: 2014-01-29
    Sponsor Name:Watson Laboratories, Inc. - A subsidiary of Actavis, Inc.
    Full Title: A Randomised, Parallel Group, Assessor-Blind, Multicentre Study to Compare the Safety and Efficacy of Watson rhFSH with Follitropin Alfa (GONAL-f) in Stimulating Multiple Follicular Development in ...
    Medical condition: Stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), gamete intra-fallopian transfer and...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038604 - Reproductive system and breast disorders 10021928 Infertility female PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) GB (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004165-13 Sponsor Protocol Number: IJB-LBC-NEOCHECKRAY-2018 Start Date*: 2019-06-06
    Sponsor Name:Institut Jules Bordet
    Full Title: Neo-adjuvant chemotherapy combined with SBRT to the primary tumour +/- durvalumab (MEDI4736), +/- oleclumab in luminal B breast cancer: a phase ll randomized trial
    Medical condition: Luminal B Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 22:09:27 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA